Posttraumatic Stress Disorder Symptoms in Lymphoma Patients: A Prospective Study.

cancer lymphoma peritraumatic dissociation peritraumatic distress posttraumatic stress disorder stressor

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2020
Historique:
received: 01 10 2019
accepted: 02 03 2020
entrez: 29 3 2020
pubmed: 29 3 2020
medline: 29 3 2020
Statut: epublish

Résumé

The cancer experience may be marked by repeat stressors and/or traumas. The aim of our study was to assess traumatic events in a group of patients diagnosed with lymphoma and to determine which of these contribute to the development of Post-Traumatic Stress Disorder/PTSD. Two weeks after receiving a diagnosis of lymphoma, patients were referred for an assessment of peritraumatic distress (using the Peritraumatic Distress Inventory/PDI) and peritraumatic dissociation (using the Peritraumatic Dissociative Experiences Questionnaire/PDEQ). Three months after the diagnosis, we recorded the following parameters: the patients' worst experiences, the presence of PTSD symptoms, using the PTSD CheckList/PCL, as it related to the diagnosis, and symptoms of anxiety using the Hospital Anxiety and Depression/HAD scale and of depression using the Beck Depression Inventory/BDI-II. The study recruited 129 patients, with a mean age of 46 years (SD = 17.3); 70 (54%) men, 87 (67.5%) with Non-Hodgkin's lymphoma, and 42 with Hodgkin's lymphoma. Two weeks after the diagnosis, 49% of patients reported peritraumatic distress, and 20% peritraumatic dissociation, during or immediately after being informed of the lymphoma diagnosis. Three months after the diagnosis, the severity of PTSD symptoms was evaluated. At this stage none of the patients suffered PTSD, but 29 (23%) individuals exhibited partial PTSD: 13.4% correlated it to receiving the lymphoma diagnosis, 8% to telling family members, and 1.6% to adverse effects. Peritraumatic distress and dissociation as a result of receiving a lymphoma diagnosis, as well as anxiety and a mucositis within the first 3 months post-diagnosis, were factors that were significantly associated with PTSD symptoms, accounting for 35.8% in PTSD symptom load. Our study reveals that clinicians should assess the impact of a number of stressors, which are risk factors for PTSD symptoms, starting from the time point of the initial lymphoma diagnosis.

Identifiants

pubmed: 32218748
doi: 10.3389/fpsyt.2020.00201
pmc: PMC7078238
doi:

Types de publication

Journal Article

Langues

eng

Pagination

201

Informations de copyright

Copyright © 2020 Camille, Dimeglio, Yrondi, Compaci, Delmas, Gauché, Laurent and Birmes.

Références

Ann Hematol. 2019 Apr;98(4):931-939
pubmed: 30778715
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Can J Psychiatry. 2005 Jan;50(1):67-71
pubmed: 15754668
J Clin Oncol. 2011 Dec 1;29(34):4526-33
pubmed: 21990412
Lancet Psychiatry. 2017 Apr;4(4):330-338
pubmed: 28109647
J Pers Assess. 1996 Dec;67(3):588-97
pubmed: 8991972
Eur Psychiatry. 2005 Mar;20(2):145-51
pubmed: 15797699
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Psychooncology. 2015 Jun;24(6):624-34
pubmed: 25393527
J Clin Oncol. 2008 Feb 20;26(6):934-41
pubmed: 18281667
Int J Biol Markers. 2013 Jun 28;28(2):168-73
pubmed: 23709344
Cancer. 2018 Jan 15;124(2):406-416
pubmed: 29152719
Psychother Psychosom. 2002 Jan-Feb;71(1):47-53
pubmed: 11740168
Front Psychiatry. 2013 Oct 02;4:122
pubmed: 24106482
Psychooncology. 2015 Apr;24(4):371-81
pubmed: 25146298
Front Psychol. 2015 Feb 24;6:118
pubmed: 25759675
J Trauma Stress. 2010 Dec;23(6):759-66
pubmed: 21171137
Leuk Res. 2013 May;37(5):496-502
pubmed: 23352641
Psychooncology. 2013 Feb;22(2):434-40
pubmed: 22162210

Auteurs

Claire Camille (C)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Chloé Dimeglio (C)

Faculté de Médecine de Toulouse, Biostatistique Informatique Médicale, Université Paul Sabatier, UMR 1027, Toulouse, France.

Antoine Yrondi (A)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Gisèle Compaci (G)

Departement d'Hématologie, Institut Universitaire du Cancer de Toulouse, Oncopôle, France.

Emmanuelle Delmas (E)

Departement d'Hématologie, Institut Universitaire du Cancer de Toulouse, Oncopôle, France.

Mélanie Gauché (M)

CERES (Culture, Ethique, Religion et Société), Institut Catholique de Toulouse, Toulouse, France.

Guy Laurent (G)

Departement d'Hématologie, Institut Universitaire du Cancer de Toulouse, Oncopôle, France.

Philippe Birmes (P)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Classifications MeSH